Bank of America
KNSA icon

Bank of America’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bank of America’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,000
Closed -$524K – 8056
2022
Q4 		$524K Buy
35,000
+10,100
+41% +$147K ﹤0.01% 5346
2022
Q3 		$320K Buy
+24,900
New +$284K ﹤0.01% 5702

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America's KNSA Position: Q1 2026 in Review

Bank of America increased its Kiniksa Pharmaceuticals (KNSA) stake by 221% in Q1 2026, buying an estimated $22.4M and bringing the position to 735,940 shares worth $35.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1888.

Bank of America first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Bank of America held 735,940 shares of Kiniksa Pharmaceuticals worth $35.4M as of Q1 2026.
  • Bank of America bought 506,576 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $22.4M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1888 holding.
  • Bank of America first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.